Physician profile
Lingmin He
NPI 1730405184
$9,038.52
in general payments reported to CMS, 2019-2025
18 companies · $5,941 in 2025
The $5,941 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $191 · 2021: $123 · 2022: $377 · 2023: $736 · 2024: $1,144 · 2025: $5,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,050 · Food and Beverage: $3,130 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,050.00 |
| Food and Beverage | $3,129.85 |
| Travel and Lodging | $641.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,954.73 | 2019-2025 | Susvimo, Vabysmo |
| Astellas Pharma US INC | $645.88 | 2023-2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $536.86 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $330.04 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $280.94 | 2022-2023 | Constellation, Ngenuity |
| Novartis Pharmaceuticals Corporation | $280.45 | 2019 | |
| Abbvie INC. | $193.49 | 2023-2025 | |
| Genentech, INC. | $154.12 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $131.02 | 2025 | Eylea, Eylea Hd |
| Mallinckrodt Hospital Products INC. | $110.18 | 2023-2025 | Acthar |
| Biogen, INC. | $100.00 | 2023 | |
| Alimera Sciences, INC. | $97.79 | 2019-2020 | |
| Harrow Eye, LLC | $74.41 | 2023-2024 | Iheezo |
| Optos, INC. | $58.34 | 2019-2020 | |
| Amgen INC. | $32.37 | 2025 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $20.16 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingmin He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.